Sumary of Pfizer to sell 10 million COVID-19 treatments to US for $5.3 bn:
- WASHINGTON – Pfizer said on Thursday it has reached an agreement to sell 10 million COVID-19 treatment courses to the US government for $5.3 billion, pending approval from regulators.
- The pharmaceutical giant asked the US Food and Drug Administration on Tuesday for emergency use authorisation for its Paxlovid antiviral pill which has been shown to cut hospitalisation or death by nearly 90% among newly-infected high risk patients treated within three days of the onset of symptoms.
- “It is encouraging to see a growing understanding of the valuable role that oral investigational therapies may play in combatting COVID-19, and we look forward to continuing discussions with governments around the world to help ensure broad access for people everywhere.
- “Pfizer will start delivering the treatments to the US government later this year and continuing through the end of 2022, the statement said.
- “This promising treatment could help accelerate our path out of this pandemic by offering another life-saving tool for people who get sick with COVID-19,” US health secretary Xavier Becerra said.
- While vaccinations remain the most important step to end the pandemic, “This agreement would help ensure millions of doses of this drug would be available to the American people if it is authorised,” he said.
- The US is also buying 3.1 million courses of the Merck pill, Molnupiravir.